Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Sales | 3,605,400 | 3,884,301 | 3,754,300 | 3,675,600 | 3,028,700 |
| Cost of Goods | 669,400 | 584,600 | 521,600 | 530,200 | 464,300 |
| Gross Profit | 2,936,000 | 3,299,700 | 3,232,700 | 3,145,400 | 2,564,400 |
| Operating Expenses | 2,293,500 | 2,420,400 | 2,206,500 | 2,066,100 | 1,973,000 |
| Operating Income | 642,900 | 879,900 | 1,026,800 | 1,079,500 | 591,700 |
| Interest Expense | 12,900 | 12,200 | 19,300 | 3,600 | 8,700 |
| Other Income | 201,200 | 176,000 | 755,800 | 442,800 | 322,000 |
| Pre-tax Income | 831,200 | 1,043,700 | 1,763,300 | 1,518,700 | 905,000 |
| Income Tax | 104,000 | 199,100 | 303,300 | 127,100 | 96,300 |
| Net Income Continuous | 727,200 | 844,600 | 1,460,000 | 1,391,600 | 808,700 |
| Net Income | $727,200 | $844,600 | $1,460,000 | $1,391,600 | $808,700 |
| EPS Basic Total Ops | 6.99 | 8.16 | 14.09 | 13.24 | 7.58 |
| EPS Basic Continuous Ops | 6.99 | 8.16 | 14.09 | 13.24 | 7.58 |
| EPS Diluted Total Ops | 6.75 | 7.78 | 13.62 | 12.81 | 7.27 |
| EPS Diluted Continuous Ops | 6.75 | 7.78 | 13.62 | 12.81 | 7.27 |
| EPS Diluted Before Non-Recurring Items | N/A | 9.30 | 9.63 | 10.72 | 6.43 |
| EBITDA(a) | $766,100 | $1,024,900 | $1,163,500 | $1,214,600 | $718,600 |